New drug may stop transplant complications in blood cancer patients
NCT ID NCT04859946
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 26 times
Summary
This study tests whether adding the drug itacitinib to standard care can prevent graft-versus-host disease (GVHD) in people who have received a donor stem cell transplant for blood disorders. GVHD happens when donor cells attack the patient's body. The trial includes 31 adults aged 18 to 70. Itacitinib is given after transplant to try to stop this attack. This is a phase 2 study, meaning it is still being tested for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC AND LYMPHOCYTIC DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.